Aug 28 (Reuters) - Novocure said on Monday its therapy, in combination with a type of chemotherapy paclitaxel, failed in a late-stage trial to meet the main goal of improving survival rates in patients with a type of ovarian cancer. (Reporting by Sriparna Roy in Bengaluru; Editing by Nivedita Bhattacharjee)